UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2013

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

Delaware	000-50679	77-0487658
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

149 Commonwealth Drive

Menlo Park, CA 94025

(Address of principal executive offices, with zip code)

(650) 327-3270

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders

On May 17, 2013, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect directors to hold office until our annual meeting of stockholders in 2014 and until their successors are qualified and elected and 2) to ratify the appointment of Ernst & Young, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2013.

A total of 99,814,250 shares of Corcept common stock held by stockholders of record at the close of business on April 10, 2013 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 92,765,109. The voting on the four matters is set forth below:

Proposal 1 – Election of Directors - The following directors were elected to serve until the 2014 annual meeting of stockholders and until their successors are elected and qualified.

	For		Withheld		Broker Non-Votes
Director:
G. Leonard Baker, Jr.		70,827,192		222,592		21,715,325
Joseph K. Belanoff, M.D.		70,822,877		226,907		21,715,325
Daniel M. Bradbury		70,865,811		183,973		21,715,325
Joseph C. Cook, Jr.		70,596,667		453,117		21,715,325
Patrick G. Enright		70,827,977		221,807		21,715,325
David L. Mahoney		70,902,921		146,863		21,715,325
Joseph L. Turner		70,907,621		142,163		21,715,325
James N. Wilson		62,667,942		8,381,842		21,715,325

Proposal 2 – To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013.

For	92,126,210
Against	481,424
Abstain	157,475
Broker Non-Votes	N/A

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CORCEPT THERAPEUTICS INCORPORATED
Date: May 21, 2013	By:	/s/ G. Charles Robb
		G. Charles Robb
		Chief Financial Officer

-3-